

# Selective synthesis of an elusive C-functionalized bis-cyclam and study of its inhibition properties of CXCR4 chemokine receptor

Marie M. Le Roy,<sup>a</sup> Sandra Claes,<sup>b</sup> Nathalie Saffon-Merceron,<sup>c</sup> Dominique Schols,<sup>\*c</sup> Thibault Troadec,<sup>\*a</sup> and Raphaël Tripier<sup>a</sup>

## Addresses :

<sup>a</sup> Univ. Brest, UMR CNRS 6521 CEMCA, 6 Avenue Victor le Gorgeu, 29200 Brest, France.

<sup>b</sup> Rega Institute for Medical Research, KU Leuven, B-3000 Leuven, Belgium

<sup>c</sup> Institut de Chimie de Toulouse (FR 2599), 118 route de Narbonne, 31062 Toulouse Cedex 9, France

*email : thibault.troadec@univ-brest.fr*

## SUPPORTING INFORMATION

### Table of content

<b>EXPERIMENTAL DETAILS .....</b>	<b>3</b>
Synthesis .....	3
Nuclear Magnetic Resonance Spectroscopy. ....	3
Mass Spectrometry.....	3
Liquid Chromatography (HPLC) .....	3
 <b>SYNTHETIC PROTOCOLS AND CHARACTERIZATION DATA FOR COMPOUNDS 1-10 .....</b>	 <b>4</b>
 <b>SPECTRAL DATA .....</b>	 <b>7</b>
 <b>COMPOUND 1: .....</b>	 <b>7</b>
<b>Figure S1:</b> <sup>1</sup> H (400 MHz, CDCl <sub>3</sub> , 298K, TMS) and <sup>13</sup> C Jmod (75 MHz, CDCl <sub>3</sub> , 298K, TMS) NMR	7
<b>Figure S2:</b> HRMS spectrum (ESI).....	8
 <b>COMPOUND 2: .....</b>	 <b>9</b>
<b>Figure S3 :</b> <sup>1</sup> H (300 MHz, CDCl <sub>3</sub> , 298K, TMS) and <sup>13</sup> C Jmod (75 MHz, CDCl <sub>3</sub> , 298K, TMS) NMR ..	9
<b>Figure S4:</b> HRMS spectrum (ESI).....	10

<b>COMPOUND 4:</b> .....	<b>11</b>
<b>Figure S5:</b> <sup>1</sup> H (300 MHz, CDCl <sub>3</sub> , 298K, TMS) and <sup>13</sup> C Jmod (75 MHz, CDCl <sub>3</sub> , 298K, TMS) NMR .	11
<b>Figure S6:</b> HRMS spectrum (ESI).....	12
<b>Table S1:</b> X-ray data of compound 4 .....	13
<b>COMPOUND 5:</b> .....	<b>14</b>
<b>Figure S7:</b> <sup>1</sup> H (400 MHz, CDCl <sub>3</sub> , 298K, TMS) and <sup>13</sup> C Jmod (125 MHz, CDCl <sub>3</sub> , 298K, TMS) NMR	14
<b>Figure S8:</b> HRMS spectrum (ESI).....	15
<b>COMPOUND 6:</b> .....	<b>16</b>
<b>Figure S9:</b> <sup>1</sup> H (400 MHz, MeOD, 298K, TMS) and <sup>13</sup> C Jmod (125 MHz, MeOD, 298K, TMS) NMR .....	16
<b>Figure S10:</b> HRMS spectrum (ESI) of compound 6.....	17
<b>COMPOUND 7:</b> .....	<b>18</b>
<b>Figure S11:</b> <sup>1</sup> H (400 MHz, CDCl <sub>3</sub> , 298K, TMS) and <sup>13</sup> C Jmod (125 MHz, CDCl <sub>3</sub> , 298K, TMS) NMR .....	18
<b>COMPOUND 9 (MIXTURE OF DIASTEREOMERS):</b> .....	<b>19</b>
<b>Figure S12:</b> <sup>1</sup> H (500 MHz, CDCl <sub>3</sub> , 298K, TMS) and <sup>13</sup> C Jmod (125 MHz, CDCl <sub>3</sub> , 298K, TMS) NMR .....	19
<b>Figure S13:</b> HRMS spectrum (ESI).....	20
<b>COMPOUND 10 (C,C'-(M-XYLYLENE)BIS-CYCLAM)</b> .....	<b>21</b>
<b>Figure S14:</b> <sup>1</sup> H (400 MHz, D <sub>2</sub> O, 298K, TMS) and <sup>13</sup> C Jmod (125 MHz, D <sub>2</sub> O, 298K, TMS) NMR ...	21
<b>Figure S15:</b> HRMS spectrum (ESI) .....	22
<b>Figure S16:</b> HPLC-ELSD chromatogram. Mobile phase H <sub>2</sub> O + 0.1% formic acid / Acetonitrile (95:5 for 16 mins, gradient to 10:90 in 6 mins + 2 mins at 10:90, gradient to 95:5 in 6 mins) .....	23
<b>BIOLOGICAL ASSAYS</b> .....	<b>24</b>
<b>Table S2:</b> Calcium Signalling Assays (3 replicates, U87.CD4.CXCR4 cells) .....	24
<b>Figure S17:</b> Calcium Signalling Assays (U87.CD4.CCR5 cells) .....	25
<b>Figure S18:</b> CXCL12 inhibition Assay (Jurkat cells).....	26
<b>Table S3:</b> Monoclonal Antibodies (mAbs) binding assays (IC <sub>50</sub> values, Jurkat cells) .....	26
<b>Figure S19:</b> Monoclonal Antibodies (mAbs) binding assays.....	27
<b>Table S4:</b> Inhibition of HIV-infection in TZM-bl, luciferase assay .....	28

## Experimental details

**Synthesis.** Reagent used for synthesis were purchased from SIGMA-ALDRICH®, TCI chemicals®, ACROS ORGANICS® and Ambeed® and used without further purification. Solvents for synthesis were obtained from a MBraun MB-SPS 800 purification system. Ultrapure water was freshly obtained from a Milli-Q dispenser.

Compounds **3** and **8** were synthesized according to previously reported procedures.<sup>38,32</sup>

**Nuclear Magnetic Resonance Spectroscopy.** NMR data were recorded at the “Service Général des Plateformes (SGPLAT)” of the Université de Bretagne Occidentale. <sup>1</sup>H, <sup>13</sup>C and 2D NMR spectra were recorded on a Bruker Avance III HD 500 (500.25 MHz for <sup>1</sup>H and 125.79 MHz for <sup>13</sup>C), Bruker Avance 400 (400.13 MHz for <sup>1</sup>H and 100.62 MHz for <sup>13</sup>C) or Bruker AMX-3 300 (300.13 MHz for <sup>1</sup>H and 75.47 MHz for <sup>13</sup>C) spectrometers. Deuterated solvents from Eurisotop® are used to reference spectra, <sup>1</sup>H and <sup>13</sup>C shifts are reported in ppm and the  $\delta$  scales are relative to TMS.

The signals are indicated as follows: chemical shift, multiplicity (s for singlet; br for broad singlet, d for doublet; t for triplet; q for quadruplet; m for multiplet), coupling constants J in Hertz (Hz), assignment: CH<sub>2</sub> $\alpha$ N, CH<sub>2</sub> $\beta$ N or CH<sub>2</sub> $\gamma$ N correspond to CH<sub>2</sub> located in alpha, beta or gamma position of considered nitrogen atom, type of nuclei is indicated in italic. Ar is a generic term used in subscript for all H or C aromatic atoms.

**Mass Spectrometry.** High-Resolution Mass Spectrometry (HRMS) analyses were performed at the Institute of Organic and Analytic Chemistry (ICOA Orléans) on a HRMS Q-ToF MaXis, sources ESI, APCI, APPI and nano-ESI. MALDI TOF were recorded at the “service commun” of the Université de Bretagne Occidentale using MALDI TOF-TOF AuTOFLEX III from Bruker Daltonics.

**Liquid Chromatography (HPLC).** HPLC analysis was carried out on Shimadzu LD20 system equipped with an Agilent Zorbax SB-C18 column (4.6 x 250 mm, 5-micron) and a Shimadzu ELSD LTII detector (80°C, N<sub>2</sub> as nebulizing gas, 350kPa). Elution with H<sub>2</sub>O (0.1% formic acid)/Acetonitrile was performed with 30 minutes program set up as: 95:5 for 16 mins, gradient to 10:90 in 6 mins + 2 mins at 10:90, gradient to 95:5 in 6 mins). Analysis and data were processed with LabSolutions software.

## Synthetic protocols and characterization data for compounds 1-10

**Synthesis of 1:** Isophthalaldehyde (1.000 g, 7.46 mmol), Meldrum Acid (2.146 g, 14.9 mmol) and Hantzsch ester (3.777 g, 14.9 mmol) were solubilized in MeOH (26 mL). Then, *L*-proline (0.172 g, 1.49 mmol, 20 %) was added and the reaction mixture was stirred at 25 °C for 12 h. The precipitate was filtered and washed with diethyl ether. The crude product was purified by column chromatography on silica gel (Hexane/Ethyl acetate/Methanol 50:50:0 to 0:90:10) to afford compound **1** as a white powder (2.460 g, 85 %).

$^1\text{H NMR}$  ( $\text{CDCl}_3$ , 400 MHz, 298 K)  $\delta$  (ppm) 7.24-7.17 (m, 4H,  $\text{CH}_{\text{Ar}}$ ), 3.77 (t, 2H, CH,  $J = 5.21$  Hz), 3.44 (d, 4H,  $\text{CH}_2$ ,  $J = 5.21$  Hz), 1.52 (s, 6H,  $\text{CH}_3$ ), 1.55 (s, 6H,  $\text{CH}_3$ ).  $^{13}\text{C Jmod NMR}$  ( $\text{CDCl}_3$ , 75 MHz, 298 K)  $\delta$  (ppm) 165.3 (CO), 137.8 ( $\text{C}_{\text{ipso}}$ ), [130.7, 129.0, 128.6 (x2)] ( $\text{CH}_{\text{Ar}}$ ), 105.4 ( $\text{C}_{\text{sp}}$ ), 48.2 (CH), 31.9 ( $\text{CH}_2$ ), [28.6, 27.2] ( $\text{CH}_3$ ). *HRMS* (ESI, positive,  $\text{H}_2\text{O}$ )  $m/z$  calcd. for  $[\text{C}_{20}\text{H}_{26}\text{NO}_8]^+$  408.1653 found  $[\text{M}+\text{NH}_4]^+$  408.1651, calcd. for  $[\text{C}_{20}\text{H}_{22}\text{NaO}_8]^+$  413.1207 found  $[\text{M}+\text{Na}]^+$  413.1207. *Mp*: 180 °C

**Synthesis of 2:** Compound **1** (2.460 g, 6.30 mmol) and Eschenmoser's salt (5.831 g, 31.5 mmol) were solubilized in MeOH (25 mL), and the reaction was stirred at 65 °C for 12 h. After cooling to room temperature, the solvent was removed under vacuum. The crude product was dissolved in  $\text{CHCl}_3$  (100 mL) and washed with  $\text{NaHCO}_3(\text{sat})$  (50 mL),  $\text{KHSO}_4(10\% \text{ weight})$  (50 mL) and  $\text{NaCl}(\text{sat})$  (50 mL). The organic layer was dried over  $\text{MgSO}_4$ , filtered, and concentrated *in vacuo* to afford compound **2** as an orange oil (1.674 g, 97 %).

$^1\text{H NMR}$  ( $\text{CDCl}_3$ , 300 MHz, 298 K)  $\delta$  (ppm) 7.22-7.19 (m, 1H,  $\text{CH}_{\text{Ar}}$ ), 7.06-7.03 (m, 3H,  $\text{CH}_{\text{Ar}}$ ), 6.22 (s, 2H, =CH), 5.43 (s, 2H, =CH), 3.73 (s, 6H,  $\text{CH}_3$ ), 3.60 (s, 4H,  $\text{CH}_2$ ).  $^{13}\text{C Jmod NMR}$  ( $\text{CDCl}_3$ , 75 MHz, 298 K)  $\delta$  (ppm) 167.3 (CO), [140.1, 138.8] ( $\text{C}_{\text{ipso}}$ ), [129.8, 128.5, 127.1 (x2)] ( $\text{CH}_{\text{Ar}}$ ), 126.2 (=CH<sub>2</sub>), 51.8 ( $\text{CH}_3$ ), 37.9 ( $\text{CH}_2\text{Ar}$ ). *HRMS* (ESI, positive,  $\text{H}_2\text{O}$ )  $m/z$  calcd. for  $[\text{C}_{16}\text{H}_{19}\text{O}_4]^+$  275.1278 found  $[\text{M}+\text{H}]^+$  275.1281, calcd. for  $[\text{C}_{12}\text{H}_{22}\text{NO}_4]^+$  292.1543 found  $[\text{M}+\text{NH}_4]^+$  292.1546, calcd. for  $[\text{C}_{16}\text{H}_{18}\text{NaO}_4]^+$  297.1097 found  $[\text{M}+\text{Na}]^+$  297.1099

**Synthesis of 4:** A solution of **2** (0.387 g, 1.41 mmol) in ethyl acetate (2 mL) was added dropwise to a solution of **3** (0.514 g, 2.82 mmol) in ethyl acetate (5 mL). The reaction was stirred at 25 °C for 4 months. The solvent was removed under reduced pressure at room temperature and the crude product was precipitated with THF. The solid was filtered off, washed with THF and dried under reduced pressure to afford compound **4** as a white solid (0.243 g, 30 %).

$^1\text{H NMR}$  ( $\text{CDCl}_3$ , 300 MHz, 298 K)  $\delta$  (ppm) 7.19-7.12 (m, 1H,  $\text{CH}_{\text{Ar}}$ ), 7.01-6.93 (m, 3H,  $\text{CH}_{\text{Ar}}$ ), 4.50 (d, 2H, CH,  $J = 13.10$  Hz), 4.32 (d, 2H, N-CH-N,  $J = 2.5$  Hz), 3.54-3.41 (m, 4H,  $\text{CH}_2\text{-Ar}$ ), 3.22 (d, 2H, N-CH-N,  $J = 2.5$  Hz), 3.19-2.09 (m, 30H,  $\text{CH}_2\alpha\text{N}$ ), 1.37-1.23 (m, 2H,  $\text{CH}_2\beta\text{N}$ ).  $^{13}\text{C Jmod NMR}$  ( $\text{CDCl}_3$ , 75 MHz, 298 K)  $\delta$  (ppm) 171.2 (CO), 139.7 ( $\text{C}_{\text{ipso}}$ ), [129.6, 128.7, 127.0] ( $\text{CH}_{\text{Ar}}$ ), [76.0, 70.6] ( $\text{CH}_{\text{cis}}$ ), 55.7 ( $\text{CH}_2\text{Ar}$ ), [54.1, 53.2, 52.9, 44.3, 44.2, 40.2] ( $\text{CH}_2\alpha\text{N}$ ), 37.0 (CH), 35.3 ( $\text{CH}_2\alpha\text{N}$ ), 19.5 ( $\text{CH}_2\beta\text{N}$ ). *HRMS* (ESI, positive,  $\text{H}_2\text{O}$ )

m/z calcd. for  $[C_{32}H_{47}N_8O_2]^+$  575.3816 found  $[M+H]^+$  575.3819, calcd. for  $[C_{32}H_{46}N_8NaO_2]^+$  597.3636 found  $[M+Na]^+$  597.3640, calcd. for  $[C_{32}H_{48}N_8O_2]^{2+}$  288.1945 found  $[M+2H]^{2+}$  288.1949

**Synthesis of 5:** A suspension of NaH (0.5018 g, 20.91 mmol) in THF (10 mL) was cooled to 0 °C and diethyl malonate (3.257 g, 20.4 mmol) was added dropwise and stirring was continued until the solution became clear. Then *m*-dibromoxylene (1.500 g, 5.10 mmol) was added, and the solution was allowed to warm to room temperature and stirred for 1 h, then heated for 18 h at 50 °C. The reaction mixture was quenched with  $NH_4Cl_{(sat)}$  and the product was extracted from the aqueous layer with ethyl acetate. The crude product was purified by flash chromatography on silica gel (Hexane/EtOAc, 100:0 to 0:100) to afford compound **5** as a colorless oil (1.1674 g, 54 %).

$^1H$  NMR ( $CDCl_3$ , 400 MHz, 298 K)  $\delta$  (ppm) 7.20-7.15 (m, 1H,  $CH_{Ar}$ ), 7.06-7.03 (m, 3H,  $CH_{Ar}$ ), 4.20-4.10 (m, 8H, O- $CH_2$ - $CH_3$ ), 3.59 (t, 2H, CH,  $J = 7.8$  Hz), 3.16 (d, 4H,  $CH_2Ar$ ,  $J = 7.8$  Hz), 1.20 (t, 12H, O- $CH_2$ - $CH_3$ ,  $J = 7.2$  Hz).  $^{13}C$  Jmod NMR ( $CDCl_3$ , 125 MHz, 298 K)  $\delta$  (ppm) 168.9 (CO), 138.3 ( $C_{ipso}$ ), [129.4, 128.7, 127.3] ( $CH_{Ar}$ ), 61.5 (O- $CH_2$ - $CH_3$ ), 53.9 (CH), 34.6 ( $CH_2Ar$ ), 14.1 (O- $CH_2$ - $CH_3$ ). HRMS (ESI, positive,  $H_2O$ ) m/z calcd. for  $[C_{22}H_{31}O_8]^+$  423.2013 found  $[M+H]^+$  423.2015, calcd. for  $[C_{22}H_{30}NaO_8]^+$  445.1832 found  $[M+Na]^+$  445.1837, calcd. for  $[C_{22}H_{30}KO_8]^+$  461.1572 found  $[M+K]^+$  461.1573

**Synthesis of 6:** A suspension of  $LiAlH_4$  (0.7329 g, 19.4 mmol) in THF (25 mL) was cooled to -10 °C and a solution of **5** (1.3635 g, 3.23 mmol) in THF (7 mL) was added dropwise. The reaction mixture was warmed slowly to room temperature (~2 h) and heated to 50 °C for 18 h. Celite® and  $Et_2O$  were added before the addition of  $H_2O$  (1 mL), HCl (3M, 1 mL),  $H_2O$  (1 mL) and the mixture was filtered off. The filtrate was concentrated under reduced pressure to afford compound **6** as a colorless oil (0.7443 g, 91 %).

$^1H$  NMR (MeOD, 400 MHz, 298 K)  $\delta$  (ppm) 7.21-7.16 (m, 1H,  $CH_{Ar}$ ), 7.09-7.01 (m, 3H,  $CH_{Ar}$ ), 3.54 (d, 8H,  $CH_2$ -OH,  $J = 5.7$  Hz), 2.62 (d, 4H,  $CH_2$ -Ar,  $J = 7.3$  Hz), 1.94-1.86 (q, 2H, CH,  $J = 7.3, 5.7$  Hz).  $^{13}C$  Jmod NMR (MeOD, 125 MHz, 298 K)  $\delta$  (ppm) 141.8 ( $C_{ipso}$ ), [131.1, 129.2, 127.8] ( $CH_{Ar}$ ), 63.1 ( $CH_2$ -OH), 46.6 (CH), 35.1 ( $CH_2$ -Ar). HRMS (ESI, positive,  $H_2O$ ) m/z calcd. for  $[C_{14}H_{23}O_4]^+$  255.1591 found  $[M+H]^+$  255.1594, calcd. for  $[C_{14}H_{22}NaO_4]^+$  277.1410 found 277.1415

**Synthesis of 7:** Compound **6** (0.350 g, 1.38 mmol) and triphenylphosphine (7.2075 g, 27.5 mmol) were solubilized in DMF (60 mL) and carbon tetrabromide (9.1275 g, 27.5 mmol) was added. The reaction was stirred at 30 °C for 18 h. The solvent was removed under reduced pressure. The crude product was dissolved in  $H_2O$  (40 mL) and extracted with dichloromethane (2 × 100 mL). Then, purification on silica gel was performed (Hexane/DCM 100:0 to 80:20) to afford compound **7** as a colorless oil (0.4362 g, 63 %).

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz, 298 K)  $\delta$  (ppm) 7.30 (m, 1H,  $\text{CH}_{\text{Ar}}$ ), 7.14-7.08 (m, 3H,  $\text{CH}_{\text{Ar}}$ ), 3.59 (dd, 4H,  $\text{CH}_2\text{-Br}$ ,  $J = 10.5, 4.6$  Hz), 3.43 (dd, 4H,  $\text{CH}_2\text{-Br}$ ,  $J = 10.5, 6.3$  Hz), 2.18 (d, 4H,  $\text{CH}_2\text{-Ar}$ ,  $J = 7.5$  Hz), 2.32-2.22 (m, 2H, CH).  $^{13}\text{C}$  Jmod NMR ( $\text{CDCl}_3$ , 125 MHz, 298 K)  $\delta$  (ppm) 138.9 ( $\text{C}_{\text{ipso}}$ ), [130.0, 129.3, 127.6] ( $\text{CH}_{\text{Ar}}$ ), 43.8 (CH), 37.5 ( $\text{CH}_2\text{-Ar}$ ), 35.8 ( $\text{CH}_2\text{-Br}$ ). MALDI-TOF (matrix: dithranol):  $m/z$  calcd for  $[\text{C}_{14}\text{H}_{19}\text{Br}_4]$  506.820 found  $[\text{M}+\text{H}]^+$  506.254


**Synthesis of 9:** To a solution of **7** (0.4362 g, 0.86 mmol) in dry acetonitrile (7.5 mL), a solution of compound **8** (0.372 g, 1.77 mmol) in dry acetonitrile (7.5 mL) was added dropwise. Then,  $\text{K}_2\text{CO}_3$  (2.3770 g, 17.2 mmol, 20 equiv.) was added and the reaction was stirred at 60 °C for 10 days.  $\text{K}_2\text{CO}_3$  was removed through filtration with cannula and filtrate was concentrated under reduced pressure. Crude product was purified by flash column chromatography on silica gel (DCM/ $\text{Et}_3\text{N}$ /MeOH 97:3:0 to 87:3:10) to afford compound **9** as a white foam (0.0836 g, 16 %).

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 500 MHz, 298 K)  $\delta$  (ppm) 7.15-7.07 (m, 1H,  $\text{CH}_{\text{Ar}}$ ), 6.99-6.81 (m, 3H,  $\text{CH}_{\text{Ar}}$ ), 3.98 (br, 1H), 3.82-3.58 (m, 3H), 3.44-3.02 (m, 5H), 2.90-2.11 (m, 31H,  $\text{CH}_2\alpha\text{N}$ ), 1.75 (br, 1H), 1.27 (s, 6H,  $\text{CH}_3$ ), 1.22 (s, 6H,  $\text{CH}_3$ ), 1.17-1.07 (m, 2H,  $\text{CH}_2\beta\text{N}$ ).  $^{13}\text{C}$  Jmod NMR ( $\text{CDCl}_3$ , 125 MHz, 298 K)  $\delta$  (ppm) [142.0 (x2), 141.9, 139.6 (x2)] ( $\text{C}_{\text{ipso}}$ ), [129.8, 129.7, 129.5, 128.3, 128.2, 126.7, 126.6, 126.4, 126.3] ( $\text{CH}_{\text{Ar}}$ ), 74.1 (N-C( $\text{CH}_3$ )-N), [55.6, 53.1, 53.0, 50.9, 50.9, 50.8, 50.7, 49.3, 46.7, 46.0, 45.0, 45.0, 44.9] ( $\text{CH}_2\alpha\text{N}$ ), 39.1 ( $\text{CH}_2\gamma\text{N}$ ), [34.4, 28.7] (CH), [18.1, 18.0] ( $\text{CH}_2\beta\text{N}$ ), [11.3, 11.1, 10.9, 10.0] ( $\text{CH}_3$ ). HRMS (ESI, positive,  $\text{H}_2\text{O}$ )  $m/z$  calcd. for  $[\text{C}_{36}\text{H}_{59}\text{N}_8]^+$  603.4857 found  $[\text{M}+\text{H}]^+$  603.4853, calcd. for  $[\text{C}_{36}\text{H}_{60}\text{N}_8]^{2+}$  302.2465 found  $[\text{M}+2\text{H}]^{2+}$  302.2466, calcd. for  $[\text{C}_{36}\text{H}_{61}\text{N}_8]^{3+}$  201.8334, found  $[\text{M}+3\text{H}]^{3+}$  201.8336.

**Synthesis of 10:** Compound **9** (0.0836 g, 0.139 mmol) was solubilized in HCl (3 M, 14 mL) and the reaction was stirred at room temperature for 24 h. An extraction with  $\text{CHCl}_3$  (3  $\times$  20 mL) was performed to remove organic impurities. Then the aqueous layer was concentrated under reduced pressure and the product was purified by flash chromatography on reversed-phase C18 silica ( $\text{H}_2\text{O}$ (0.1 % formic acid)/ $\text{CH}_3\text{CN}$  100:0 to 0:100) to afford compound **C,C'-(*m*-xylylene)bis-cyclam** as a brown film (0.071 g, 59 %).

$^1\text{H}$  NMR ( $\text{D}_2\text{O}$ , 500 MHz, 298 K)  $\delta$  (ppm) 8.18 (s, 0.3H,  $\text{HCOOH}$ ), 7.38 (m, 1H,  $\text{CH}_{\text{Ar}}$ ), 7.31-7.22 (m, 3H,  $\text{CH}_{\text{Ar}}$ ), 3.70-3.54 (m, 13H), 3.53-3.33 (m, 20H), 3.28-3.18 (m, 6H), 3.00-2.85 (m, 6H), 2.28 (br, 4H,  $\text{CH}_2\beta\text{N}$ ).  $^{13}\text{C}$  Jmod NMR ( $\text{D}_2\text{O}$ , 125 MHz, 298 K)  $\delta$  (ppm) 140.3 ( $\text{C}_{\text{ipso}}$ ), [132.9, 132.4, 131.0] ( $\text{CH}_{\text{Ar}}$ ), [50.5, 45.4, 44.5, 43.5] ( $\text{CH}_2\alpha\text{N}$ ), 38.4 ( $\text{CH}_2\gamma\text{N}$ ), 36.1 (CH), 22.6 ( $\text{CH}_2\beta\text{N}$ ). HRMS (ESI, positive,  $\text{H}_2\text{O}$ )  $m/z$  calcd. for  $[\text{C}_{28}\text{H}_{56}\text{N}_8]^+$  252.2308 found  $[\text{M}+2\text{H}]^{2+}$  252.2309, calcd. for  $[\text{C}_{28}\text{H}_{57}\text{N}_8]^{3+}$  168.4897 found  $[\text{M}+3\text{H}]^{3+}$  168.4902, calcd. for  $[\text{C}_{28}\text{H}_{58}\text{N}_8]^{4+}$  126.6191 found  $[\text{M}+4\text{H}]^{4+}$  126.6192.

**Spectral data**  
**Compound 1:**




Formula: C<sub>20</sub>H<sub>22</sub>O<sub>8</sub>

Molecular Weight: 390.39 g.mol<sup>-1</sup>

Description: white powder

Yield: 85%



**Figure S1:** <sup>1</sup>H (400 MHz, CDCl<sub>3</sub>, 298K, TMS) and <sup>13</sup>C Jmod (75 MHz, CDCl<sub>3</sub>, 298K, TMS) NMR






Analysis Info

Sample Name MLR087  
Analysis Name X057700CYC.d

Acquisition Date 30/09/2020 14:41:04  
Instrument / Ser# maXis 255552.00086  
Method Positif.m

Acquisition Parameter

Source Type ESI Ion Polarity Positive Set Nebulizer 0.6 Bar  
Scan Begin 50 m/z Set Capillary 4500 V Set Dry Heater 200 °C  
Scan End 3000 m/z Set Collision Cell RF 1800.0 Vpp Set Dry Gas 7.0 l/min




Meas. m/z	z	#	Ion Formula	m/z	err [ppm]	mSigma	rdb	e <sup>-</sup> Conf
159.080450	1+	1	C11H11O	159.080441	-0.1	5.0	7.0	even
187.075625	1+	1	C12H11O2	187.075356	-1.4	3.0	8.0	even
213.055019	1+	1	C13H9O3	213.054621	-1.9	6.9	10.0	even
231.065468	1+	1	C13H11O4	231.065185	-1.2	4.5	9.0	even
252.123189	1+	1	C13H18NO4	252.123034	-0.6	4.4	6.0	even
257.044711	1+	1	C14H9O5	257.044450	-1.0	12.9	11.0	even
275.055283	1+	1	C14H11O6	275.055014	-1.0	8.2	10.0	even
311.088689	1+	1	C16H16NaO5	311.088994	1.0	14.6	9.0	even

Figure S2: HRMS spectrum (ESI)



## Compound 2:



Formula: C<sub>16</sub>H<sub>18</sub>O<sub>4</sub>

Molecular Weight: 274.32 g.mol<sup>-1</sup>

Description: orange oil

Yield: 97%




Figure S3 : <sup>1</sup>H (300 MHz, CDCl<sub>3</sub>, 298K, TMS) and <sup>13</sup>C Jmod (75 MHz, CDCl<sub>3</sub>, 298K, TMS) NMR






Analysis Info

Sample Name MLR 090  
Analysis Name X057698CYC.d

Acquisition Date 30/09/2020 14:38:11  
Instrument / Ser# maXis 255552.00086  
Method Positif.m

Acquisition Parameter


Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.6 Bar
Scan Begin	50 m/z	Set Capillary	4500 V	Set Dry Heater	200 °C
Scan End	3000 m/z	Set Collision Cell RF	1800.0 Vpp	Set Dry Gas	7.0 l/min



Meas. m/z	z	#	Ion Formula	m/z	err [ppm]	mSigma	rdb	e <sup>-</sup>	Conf
155.085538	1+	1	C12H11	155.085527	-0.1	10.7	8.0	even	
183.080661	1+	1	C13H11O	183.080441	-1.2	8.2	9.0	even	
211.075657	1+	1	C14H11O2	211.075356	-1.4	0.4	10.0	even	
243.101807	1+	1	C15H15O3	243.101571	-1.0	4.4	9.0	even	
275.128171	1+	1	C16H19O4	275.127786	-1.4	2.0	8.0	even	
292.154572	1+	1	C16H22NO4	292.154335	-0.8	3.0	7.0	even	
297.109978	1+	1	C18H18NaO4	297.109730	-0.8	2.4	8.0	even	

Figure S4: HRMS spectrum (ESI)

### Compound 4:



Formula: C<sub>32</sub>H<sub>46</sub>N<sub>8</sub>O<sub>2</sub>

Molecular Weight: 574.77 g.mol<sup>-1</sup>

Description: white solid

Yield: 30 %




Figure S5: <sup>1</sup>H (300 MHz, CDCl<sub>3</sub>, 298K, TMS) and <sup>13</sup>C Jmod (75 MHz, CDCl<sub>3</sub>, 298K, TMS) NMR





Analysis Info

Sample Name **MLR 095**  
Analysis Name X058842Cyc.d

Acquisition Date 06/01/2021 17:29:04  
Instrument / Ser# maXis 255552.00086  
Method Positif.m

Acquisition Parameter

Source Type ESI Ion Polarity Positive Set Nebulizer 0.6 Bar  
Scan Begin 50 m/z Set Capillary 4500 V Set Dry Heater 200 °C  
Scan End 3000 m/z Set Collision Cell RF 1800.0 Vpp Set Dry Gas 7.0 l/min




Meas. m/z	z	#	Ion Formula	m/z	err [ppm]	mSigma	rdb	e <sup>-</sup>	Conf
288.194939	2+	1	C32H48N8O2	288.194463	-1.7	14.3	14.0	even	
575.381999	1+	1	C32H47N8O2	575.381649	-0.6	9.8	14.0	even	
597.364017	1+	1	C32H46N8NaO2	597.363593	-0.7	11.1	14.0	even	

Figure S6: HRMS spectrum (ESI)

**Table S1:** X-ray data of compound 4

Empirical formula	C <sub>32</sub> H <sub>46</sub> N <sub>8</sub> O <sub>2</sub> , C <sub>4</sub> H <sub>8</sub> O <sub>2</sub>
Formula weight	662.87
Temperature	193(2) K
Wavelength	0.71073 Å
Crystal system	Triclinic
Space group	$P \bar{1}$
Unit cell dimensions	a = 10.1829(8) Å $\alpha$ = 63.913(2)° b = 13.8753(10) Å $\beta$ = 89.426(2)° c = 14.2627(10) Å $\gamma$ = 73.285(2)°
Volume	1717.5(2) Å <sup>3</sup>
Z	2
Density (calculated)	1.282 Mg/m <sup>3</sup>
Absorption coefficient	0.086 mm <sup>-1</sup>
F(000)	716
Crystal size	0.200 x 0.180 x 0.100 mm <sup>3</sup>
Theta range for data collection	1.604 to 29.155°
Index ranges	-13<=h<=13, -17<=k<=18, -14<=l<=19
Reflections collected	53091
Independent reflections	9117 [R(int) = 0.0568]
Completeness to theta = 25.242°	99.5 %
Absorption correction	Semi-empirical from equivalent
Max. and min. transmission	0.7458 and 0.6737
Refinement method	Full-matrix least-squares on F <sup>2</sup>
Data / restraints / parameters	9117 / 0 / 435
Goodness-of-fit on F <sup>2</sup>	1.032
Final R indices [I>2sigma(I)]	R1 = 0.0797, wR2 = 0.2293
R indices (all data)	R1 = 0.1323, wR2 = 0.2686
Extinction coefficient	n/a
Largest diff. peak and hole	0.780 and -0.578 e.Å <sup>-3</sup>

### Compound 5:




Formula: C<sub>22</sub>H<sub>30</sub>O<sub>9</sub>

Molecular Weight: 422.47 g.mol<sup>-1</sup>

Description: colorless oil

Yield: 54 %



**Figure S7:** <sup>1</sup>H (400 MHz, CDCl<sub>3</sub>, 298K, TMS) and <sup>13</sup>C Jmod (125 MHz, CDCl<sub>3</sub>, 298K, TMS) NMR





**Analysis Info**

Sample Name **MLR 194**  
Analysis Name X063723CYC.d

Acquisition Date 01/12/2021 18:25:31  
Instrument / Ser# maXis 255552.00086  
Method Positif.m

**Acquisition Parameter**

Source Type ESI Ion Polarity Positive Set Nebulizer 0.6 Bar  
Scan Begin 50 m/z Set Capillary 4500 V Set Dry Heater 200 °C  
Scan End 3000 m/z Set Collision Cell RF 1800.0 Vpp Set Dry Gas 7.0 l/min




Meas. m/z	z	#	Ion Formula	m/z	err [ppm]	mSigma	rdb	e <sup>-</sup> Conf
331.117474	1+	1	C18H19O6	331.117615	0.4	32.5	10.0	even
377.159659	1+	1	C20H25O7	377.159480	-0.5	27.7	9.0	even
423.201542	1+	1	C22H31O8	423.201344	-0.5	16.5	8.0	even
440.228285	1+	1	C22H34NO8	440.227893	-0.9	n.a.	7.0	even
445.183744	1+	1	C22H30NaO8	445.183289	-1.0	11.9	8.0	even
461.157381	1+	1	C22H30KO8	461.157226	-0.3	26.6	8.0	even

Figure S8: HRMS spectrum (ESI)

## Compound 6:


Formula: C<sub>14</sub>H<sub>22</sub>O<sub>4</sub>



Molecular Weight: 254.33 g.mol<sup>-1</sup>

Description: colorless oil

Yield: 91%



**Figure S9:** <sup>1</sup>H (400 MHz, MeOD, 298K, TMS) and <sup>13</sup>C Jmod (125 MHz, MeOD, 298K, TMS) NMR







**Analysis Info**

Sample Name **MLR 195 f4**  
Analysis Name X063722CYC.d

Acquisition Date 01/12/2021 18:24:05  
Instrument / Ser# maXis 255552.00086  
Method Positif.m

**Acquisition Parameter**


Source Type ESI Ion Polarity Positive Set Nebulizer 0.6 Bar  
Scan Begin 50 m/z Set Capillary 4500 V Set Dry Heater 200 °C  
Scan End 3000 m/z Set Collision Cell RF 1800.0 Vpp Set Dry Gas 7.0 l/min



Meas. m/z	z	#	Ion Formula	m/z	err [ppm]	mSigma	rdb	e <sup>-</sup> Conf
143.085010	1+	1	C11H11	143.08527	3.6	35.1	7.0	even
171.116683	1+	1	C13H15	171.116827	0.8	124.5	7.0	even
183.116782	1+	1	C14H15	183.116827	0.2	6.4	8.0	even
201.127602	1+	1	C14H17O	201.127392	-1.0	8.5	7.0	even
219.138264	1+	1	C14H19O2	219.137956	-1.4	n.a.	6.0	even
237.147600	1+	1	C14H21O3	237.148521	3.9	n.a.	5.0	even
255.159479	1+	1	C14H23O4	255.159086	-1.5	21.6	4.0	even
277.141462	1+	1	C14H22NaO4	277.141030	-1.6	3.0	4.0	even

Figure S10: HRMS spectrum (ESI) of compound 6

### Compound 7:




Formula: C<sub>14</sub>H<sub>18</sub>Br<sub>4</sub>

Molecular Weight: 505.91 g.mol<sup>-1</sup>

Description: colorless oil

Yield: 63 %



**Figure S11:** <sup>1</sup>H (400 MHz, CDCl<sub>3</sub>, 298K, TMS) and <sup>13</sup>C Jmod (125 MHz, CDCl<sub>3</sub>, 298K, TMS) NMR



**Compound 9 (mixture of diastereomers):**

Formula: C<sub>36</sub>H<sub>58</sub>N<sub>8</sub>

Molecular Weight: 602.92 g.mol<sup>-1</sup>

Description: white foam

Yield: 16 %



**Figure S12:** <sup>1</sup>H (500 MHz, CDCl<sub>3</sub>, 298K, TMS) and <sup>13</sup>C Jmod (125 MHz, CDCl<sub>3</sub>, 298K, TMS) NMR






**Analysis Info**

Sample Name **MLR 255**  
Analysis Name X067118Cyc.d

Acquisition Date 01/06/2022 12:37:39  
Instrument / Ser# maXis 255552.00086  
Method Positif.m

**Acquisition Parameter**

Source Type ESI Ion Polarity Positive Set Nebulizer 0.6 Bar  
Scan Begin 50 m/z Set Capillary 4500 V Set Dry Heater 200 °C  
Scan End 3000 m/z Set Collision Cell RF 1800.0 Vpp Set Dry Gas 7.0 l/min



Meas. m/z	z	#	Ion Formula	m/z	err [ppm]	mSigma	rdb	e <sup>-</sup>	Conf
201.833568	3+	1	C36H61N8	201.833424	-0.7	14.3	12.0	even	
302.246641	2+	1	C36H60N8	302.246498	-0.5	26.9	12.0	even	
601.469153	1+	1	C36H57N8	601.470070	1.5	48.5	13.0	even	
	1+	2	C35H61N4O4	601.468733	-0.7	621.4	8.0	even	
603.485257	1+	1	C36H59N8	603.485720	0.8	9.1	12.0	even	
	1+	2	C35H63N4O4	603.484383	-1.4	20.6	7.0	even	
637.446645	1+	1	C35H62CIN4O4	637.445411	-1.9	193.3	7.0	even	
	1+	2	C36H58CIN8	637.446748	0.2	194.7	12.0	even	

Figure S13: HRMS spectrum (ESI)

# Compound 10 (C,C'-(*m*-xylylene)bis-cyclam)

Formula: C<sub>28</sub>H<sub>54</sub>N<sub>8</sub>

Molecular Weight: 871.0 g.mol<sup>-1</sup> (for x = 8)

Description: brown film

Yield: 59 %





Figure S14: <sup>1</sup>H (400 MHz, D<sub>2</sub>O, 298K, TMS) and <sup>13</sup>C Jmod (125 MHz, D<sub>2</sub>O, 298K, TMS) NMR






**Analysis Info**

Sample Name **MLR 215 f1**  
Analysis Name X065428CYC\_D.d

Acquisition Date 23/02/2022 14:41:40  
Instrument / Ser# maXis 255552.00086  
Method Positif.m

**Acquisition Parameter**

Source Type ESI Ion Polarity Positive Set Nebulizer 0.6 Bar  
Scan Begin 50 m/z Set Capillary 4500 V Set Dry Heater 200 °C  
Scan End 3000 m/z Set Collision Cell RF 1800.0 Vpp Set Dry Gas 7.0 l/min




Meas. m/z	z	#	Ion Formula	m/z	err [ppm]	mSigma	rdb	e <sup>-</sup>	Conf
122.362738	4+	1	C28H55N7	122.362425	-2.6	37.5	7.0	even	
126.619239	4+	1	C28H58N8	126.619062	-1.4	45.5	6.0	even	
136.875549	4+	1	C30H61N9	136.875700	1.1	12.0	7.0	even	
162.814381	3+	1	C28H54N7	162.814141	-1.5	23.4	7.0	even	
168.490208	3+	1	C28H57N8	168.489658	-3.3	56.1	6.0	even	
182.165273	3+	1	C30H60N9	182.165174	-0.5	52.6	7.0	even	
252.230881	2+	1	C28H56N8	252.230848	-0.1	5.5	6.0	even	

Figure S15: HRMS spectrum (ESI)

**Nb:** Compound 10 is not UV-active at the concentrations used for HPLC identification, therefore detection was performed with ELSD.

**==== Shimadzu LabSolutions Data Image ====**



**Figure S16:** HPLC-ELSD chromatogram. Mobile phase H<sub>2</sub>O + 0.1% formic acid / Acetonitrile (95:5 for 16 mins, gradient to 10:90 in 6 mins + 2 mins at 10:90, gradient to 95:5 in 6 mins)

## Biological Assays

**Table S2:** Calcium Signalling Assays (3 replicates, U87.CD4.CXCR4 cells)

<b>n = 1</b>					
Group Name	Concentration (nM)	Average	Minus Neg Contrl	%inhibition	IC50
Negative Control CXCL12		15,58 91,99	0 76,41		
compound 10	50 µM	14,36	-1,22	101,60	2,34 µM
	10 µM	30,81	15,23	80,07	
	2 µM	56,32	40,74	46,68	
	0,4 µM	88,17	72,59	5,00	
	0,08 µM	90,95	75,37	1,36	
	0,016 µM	80,96	65,38	14,44	
	0,0032 µM	85,77	70,19	8,14	
	0,00064 µM	74,91	59,33	22,35	
AMD3100	2000 nM	16,7	1,12	98,53	146,38 nM
	400 nM	40,7	25,12	67,12	
	80 nM	61,65	46,07	39,71	
	16 nM	83,25	67,67	11,44	


<b>n = 2</b>					
Group Name	Concentration (nM)	Average	Minus Neg Contrl	%inhibition	IC50
Negative Control CXCL12		19,24 101,07	0,00 81,83		
compound 10	50 µM	14,91	-4,33	105,29	4,43 µM
	10 µM	29,93	10,69	86,94	
	2 µM	89,6	70,36	14,02	
	0,4 µM	105,57	86,33	-5,5	
	0,08 µM	102,25	83,01	-1,44	
	0,016 µM	105,73	86,49	-5,69	
	0,0032 µM	116,5	97,26	-18,86	
	0,00064 µM	122,12	102,88	-25,77	
AMD3100	2000 nM	22,69	3,45	95,78	133,75 nM
	400 nM	35,08	15,84	80,65	
	80 nM	71,92	52,68	35,62	
	16 nM	90,92	71,68	12,41	

<b>n = 3</b>					
Group Name	Concentration (nM)	Average	Minus Neg Contrl	%inhibition	IC50
Negative Control CXCL12		19,47 93,25	0 73,78		
compound 10	50 µM	18,8	-0,67	100,91	3,98 µM
	10 µM	34,27	14,8	79,94	
	2 µM	72,81	53,34	27,70	
	0,4 µM	93,5	74,03	-0,34	
	0,08 µM	87,93	68,46	7,21	
	0,016 µM	92,8	73,33	0,61	




**Figure S17: Calcium Signalling Assays (U87.CD4.CCR5 cells)**


**Compound 10 (20  $\mu$ M)+ LD78beta (50 ng/ml)**




**Compound 10 (20  $\mu$ M- 4  $\mu$ M)+ LD78beta (50 ng/ml)**



**Maraviroc (8 nM- 1.6 nM-0.32 nM) + LD78beta (50 ng/ml) – Positive control**



**Figure S18: CXCL12 inhibition Assay (Jurkat cells)**



**Table S3: Monoclonal Antibodies (mAbs) binding assays (IC<sub>50</sub> values, Jurkat cells)**

**12G5**

	AVERAGE		
	IC <sub>50</sub> (nM)	IC <sub>50</sub> (nM)	IC <sub>50</sub> (nM)
compound 10	341,3	411,7	<b>376,5</b>
AMD3100	6,8	6,8	<b>6,8</b>

**44717**

	AVERAGE		
	IC <sub>50</sub> (nM)	IC <sub>50</sub> (nM)	IC <sub>50</sub> (nM)
compound 10	954,1	405,6	<b>679,9</b>
AMD3100	110,0	16,6	<b>63,3</b>


**1D9**

	AVERAGE		
	IC <sub>50</sub> (nM)	IC <sub>50</sub> (nM)	IC <sub>50</sub> (nM)
compound 10	> 12 000	> 20 000	<b>&gt; 20 000</b>
AMD3100	> 12 000	> 20 000	<b>&gt; 20 000</b>

**2B11**

	AVERAGE		
	IC <sub>50</sub> (nM)	IC <sub>50</sub> (nM)	IC <sub>50</sub> (nM)
compound 10	> 12 000	> 20 000	<b>&gt; 20 000</b>
AMD3100	> 12 000	> 20 000	<b>&gt; 20 000</b>

**Figure S19: Monoclonal Antibodies (mAbs) binding assays**



**Table S4:** Inhibition of HIV-infection in TZM-bl, luciferase assay

	NL4.3WT		BaL		Toxicity	
	IC <sub>50</sub> (μM)	IC <sub>50</sub> (μM)	IC <sub>50</sub> (μM)	IC <sub>50</sub> (μM)	CC <sub>50</sub> (μM)	CC <sub>50</sub> (μM)
compound 1	<b>0,11</b>	<b>0,082</b>	<b>&gt;20</b>	<b>&gt;20</b>	<b>71,74</b>	<b>&gt;100</b>
AMD3100	<b>0,00043</b>	<b>0,00031</b>	-	-	<b>&gt;100</b>	